GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » PharmaCyte Biotech Inc (NAS:PMCB) » Definitions » Net-Net Working Capital

PMCB (PharmaCyte Biotech) Net-Net Working Capital : $1.91 (As of Jan. 2025)


View and export this data going back to 2003. Start your Free Trial

What is PharmaCyte Biotech Net-Net Working Capital?

In calculating the Net-Net Working Capital (NNWC), Benjamin Graham assumed that a company's accounts receivable is only worth 75% its value, its inventory is only worth 50% of its value, but its liabilities have to be paid in full. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. This is a conservative way of estimating the company's value.

PharmaCyte Biotech's Net-Net Working Capital for the quarter that ended in Jan. 2025 was $1.91.

The industry rank for PharmaCyte Biotech's Net-Net Working Capital or its related term are showing as below:

PMCB's Price-to-Net-Net-Working-Capital is ranked better than
94.87% of 878 companies
in the Biotechnology industry
Industry Median: 4.02 vs PMCB: 0.55

PharmaCyte Biotech Net-Net Working Capital Historical Data

The historical data trend for PharmaCyte Biotech's Net-Net Working Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PharmaCyte Biotech Net-Net Working Capital Chart

PharmaCyte Biotech Annual Data
Trend Apr15 Apr16 Apr17 Apr18 Apr19 Apr20 Apr21 Apr22 Apr23 Apr24
Net-Net Working Capital
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.17 0.93 4.09 4.02 2.23

PharmaCyte Biotech Quarterly Data
Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24 Oct24 Jan25
Net-Net Working Capital Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.49 2.23 1.32 1.31 1.91

Competitive Comparison of PharmaCyte Biotech's Net-Net Working Capital

For the Biotechnology subindustry, PharmaCyte Biotech's Price-to-Net-Net-Working-Capital, along with its competitors' market caps and Price-to-Net-Net-Working-Capital data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


PharmaCyte Biotech's Price-to-Net-Net-Working-Capital Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, PharmaCyte Biotech's Price-to-Net-Net-Working-Capital distribution charts can be found below:

* The bar in red indicates where PharmaCyte Biotech's Price-to-Net-Net-Working-Capital falls into.


;
;

PharmaCyte Biotech Net-Net Working Capital Calculation

PharmaCyte Biotech's Net-Net Working Capital (NNWC) per share for the fiscal year that ended in Apr. 2024 is calculated as

Net-Net Working Capital(A: Apr. 2024 )
=(Cash, Cash Equivalents, Marketable Securities+0.75 * Accounts Receivable+0.5 * Total Inventories-Total Liabilities
-Preferred Stock-Minority Interest)/Shares Outstanding (EOP)
=(50.18+0.75 * 0+0.5 * 0-20.389
-11.867-0)/8.038
=2.23

PharmaCyte Biotech's Net-Net Working Capital (NNWC) per share for the quarter that ended in Jan. 2025 is calculated as

Net-Net Working Capital(Q: Jan. 2025 )
=(Cash, Cash Equivalents, Marketable Securities+0.75 * Accounts Receivable+0.5 * Total Inventories-Total Liabilities
-Preferred Stock-Minority Interest)/Shares Outstanding (EOP)
=(16.756+0.75 * 0+0.5 * 0-3.578
-0-0)/6.905
=1.91

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In calculating the Net-Net Working Capital (NNWC), Benjamin Graham assumed that a company's accounts receivable is only worth 75% its value, its inventory is only worth 50% of its value, but its liabilities have to be paid in full.

In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.

This is a conservative way of estimating the company's value.


PharmaCyte Biotech  (NAS:PMCB) Net-Net Working Capital Explanation

One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.

Benjamin Graham looked for companies whose market values were less than two-thirds of their net-net value. They are collected under our Net-Net screener.


PharmaCyte Biotech Net-Net Working Capital Related Terms

Thank you for viewing the detailed overview of PharmaCyte Biotech's Net-Net Working Capital provided by GuruFocus.com. Please click on the following links to see related term pages.


PharmaCyte Biotech Business Description

Traded in Other Exchanges
N/A
Address
3960 Howard Hughes Parkway, Suite 500, Las Vegas, NV, USA, 89169
PharmaCyte Biotech Inc is a clinical-stage biotechnology company. The company is focused on developing and preparing to commercialize cellular therapies for cancer and diabetes based on a proprietary cellulose-based live cell encapsulation technology called Cell-in-a-Box. The Cell-in-a-Box technology is intended to be used as a platform upon which therapies for several types of cancer, including inoperable pancreatic cancer, and diabetes will be developed. The company is developing therapies for the pancreas and other solid cancerous tumors involving the encapsulation of live cells placed in the body to enable the delivery of cancer-killing drugs at the source of cancer.
Executives
Wayne Remell Walker director 1515 MARKET STREET, SUITE 1720, PHILADELPHIA PA 19103
Robert Weinstein director 3960 HOWARD HUGHES PARKWAY, SUITE 500, LAS VEGAS NV 89169
Jack E Stover director C/O SICOR INC, 19 HUGHES, IRVINE CA 92618-1902
Daniel Stuart Farb director 100 ESSEX RD., CHESTNUT HILL MA 02467
Jonathan Schechter director C/O ATRINSIC, INC. 1 GRAND CENTRAL PLACE, SUITE 2319, NEW YORK NY 10165
Daniel Allen director 299 PARK AVENUE SOUTH, SUITE 90959, NEW YORK NY 10003
Joshua Silverman director IROQUOIS CAPITAL MANAGEMENT LLC, 205 EAST 42ND ST - 20TH FL., NEW YORK NY 10017
Matthias Loehr director 3960 HOWARD HUGHES PARKWAY, SUITE 500, LAS VEGAS NV 89169
Yuen Thomas C K director
Carlos Trujillo director, officer: CFO 8105 IRVINE CENTER DR. #820, IRVINE CA 92618
Kenneth L. Waggoner director, officer: Chairman, CEO, Pres and GC 8105 IRVINE CENTER DR. #820, IRVINE CA 92618
Gerald W Crabtree director, officer: Chief Science Officer 12510 PROSPERITY DR., SUITE #310, SILVER SPRING MD 20904
Thomas Liquard director C/O PHARMACYTE BIOTECH INC., 23046 AVENIDA DE LE CORLOTA, LAGUNA HILLS CA 92653
Raymond Cf Tong director C/O PHARMACYTE BIOTECH INC., 23046 AVENIDA DE LE CORLOTA, LAGUNA HILLS CA 10041-0099
Michael M Abecassis director C/O PHARMACYTE BIOTECH INC., 23046 AVENIDA DE LE CORLOTA, LAGUNA HILLS CA 10041-0099